The return of $10B-plus drug deals may be here as pharmaceutical companies appear to be gearing...
The return of $10B-plus drug deals may be here as pharmaceutical companies appear to be gearing up to start buying again. Five of the largest U.S. drug makers have spent the last several years building up their cash positions in anticipation of expiring patents. Now, with nearly $70B in cash equivalents at their disposal, all eyes are on JPMorgan’s annual health-care conference in San Francisco, where the big drug makers will likely be on the hunt for assets to fill revenue holes left by expired patents.
From other sites
at CNBC.com (Apr 10, 2015)
at Zacks.com (Apr 8, 2015)
at Zacks.com (Apr 7, 2015)
at Investopedia (Apr 7, 2015)
at MarketRealist.com (Mar 27, 2015)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs